New Vaccine for Individuals with Mild Alzheimer’s Disease

A 90-week, multi-center, randomized, double-blind, placebo-controlled, parallel group study in patients with mild Alzheimer’s disease (AD) to investigate the safety, efficacy, and antibody response to seven injections of CAD106 in combination with an adjuvant.

This is a 90-week placebo-controlled study evaluating IM injections of a vaccine for patients with mild Alzheimer’s. If enrolled in the study, the likelihood of receiving active drug is 7 out of 8.

Major Inclusion/ Exclusion Criteria:

  • Below 85 years of age
  • MMSE 20-26 inclusive
  • Auto-immune disease is excluded
  • More than 2 cerebral micro-hemorrhages on MRI will exclude the patient